Sigma Planning Corp Has $1.01 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Sigma Planning Corp cut its position in Novo Nordisk A/S (NYSE:NVO) by 24.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,755 shares of the company’s stock after selling 3,842 shares during the quarter. Sigma Planning Corp’s holdings in Novo Nordisk A/S were worth $1,011,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in NVO. Autumn Glory Partners LLC raised its stake in Novo Nordisk A/S by 39.9% in the third quarter. Autumn Glory Partners LLC now owns 22,671 shares of the company’s stock valued at $2,699,000 after buying an additional 6,463 shares during the period. Old Port Advisors raised its stake in Novo Nordisk A/S by 4.8% in the 3rd quarter. Old Port Advisors now owns 5,094 shares of the company’s stock valued at $607,000 after acquiring an additional 233 shares during the period. Traynor Capital Management Inc. lifted its holdings in Novo Nordisk A/S by 3.4% during the 3rd quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock valued at $36,364,000 after purchasing an additional 10,019 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Novo Nordisk A/S by 5.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,000 shares of the company’s stock worth $2,500,000 after purchasing an additional 1,000 shares during the period. Finally, Fidelis Capital Partners LLC boosted its position in Novo Nordisk A/S by 107.0% during the third quarter. Fidelis Capital Partners LLC now owns 20,313 shares of the company’s stock worth $2,351,000 after purchasing an additional 10,500 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 0.4 %

NYSE NVO opened at $90.94 on Wednesday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market cap of $408.07 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 0.90 and a beta of 0.45. The company has a 50 day moving average of $85.32 and a 200-day moving average of $107.42. Novo Nordisk A/S has a 1-year low of $77.82 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.